Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule
                                  5635(c)(4)

PR Newswire

ALISO VIEJO, Calif., Oct. 4, 2013

ALISO VIEJO, Calif., Oct. 4, 2013 /PRNewswire/ --Avanir Pharmaceuticals, Inc.
(NASDAQ: AVNR) Avanir announced that on October 1, 2013, the Company approved
the grant of stock options to new employees to purchase a total of 39,400
shares of common stock in the aggregate. The stock options were granted as
inducements material to the new employees entering into employment with
Avanir, as permitted under NASDAQ Listing Rule 5635(c)(4).

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

Avanir granted to four new employees an option to purchase shares of Avanir's
common stock with an exercise price equal to $4.38, the closing price per
share of Avanir's common stock as reported by NASDAQ on October 1, 2013, the
date of grant. Each of the options will vest with respect to one-quarter of
the underlying shares on the first anniversary of the grant date and then with
respect to the remaining shares quarterly thereafter over the following three
years, assuming in each case the employee remains continuously employed by
Avanir.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on
bringing innovative medicines to patients with central nervous system
disorders of high unmet medical need. As part of our commitment, we have
extensively invested in our pipeline and are dedicated to advancing medicines
that can substantially improve the lives of patients and their loved ones. For
more information about Avanir, please visit www.avanir.com.

AVANIR^® is a trademark or registered trademark of Avanir Pharmaceuticals,
Inc. in the United States and other countries.

©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Forward Looking Statements

Except for the historical information contained herein, the matters set forth
in this press release, including statements regarding Avanir's plans,
potential opportunities, financial or other expectations, projections, goals
objectives, milestones, strategies, market growth, timelines, legal matters,
product pipeline, clinical studies, product development and the potential
benefits of its commercialized products and products under development are
forward-looking statements within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to risks and uncertainties that may cause actual
results to differ materially, including the risks and uncertainties associated
with Avanir's operating performance and financial position, the market demand
for and acceptance of Avanir's products domestically and internationally,
research, development and commercialization of new products domestically and
internationally, obtaining additional indications, obtaining and maintaining
regulatory approvals domestically and internationally, and other risks
detailed from time to time in the Company's most recent Annual Report on Form
10-K and other documents subsequently filed with or furnished to the
Securities and Exchange Commission. These forward-looking statements are based
on current information that may change and you are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the
date of this press release. All forward-looking statements are qualified in
their entirety by this cautionary statement, and the Company undertakes no
obligation to revise or update any forward-looking statement to reflect events
or circumstances after the issuance of this press release.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700

SOURCE Avanir Pharmaceuticals, Inc.

Website: http://www.avanir.com